NEW PRESS RELEASE 1/27/00
Sunrise Technologies International, Inc. Awarded Recommendation for ISO 9001 and EN 46001 Certification
FREMONT, Calif.--(BUSINESS WIRE)--Jan. 27, 2000--Sunrise Technologies International, Inc. (NASDAQ/NMS:SNRS) -- today announced that it has passed it's ISO9001/EN46001 certification audit for the Company's Quality system will be for certified for the International Organization for Standards ISO 9001, European Commission EN 46001, and CE marking (European Community Seal of approval). These standards are internationally recognized as a symbol of conformance to strict standards of quality assurance, product development, production and servicing.
Sunrise was awarded this recommendation for certification by TUV Essen, a European Union notified body, after a rigorous audit at the Sunrise headquarters. ISO 9001/EN 46001 certification is an essential element for competing in worldwide markets.
"Our employees are to be congratulated for their hard work in achieving this international certification. This important milestone underscores our commitment to quality products, sales and service," said C. Russell Trenary III, Sunrise President and Chief Executive Officer.
This compliance certifies that regulatory quality control systems have been incorporated into the production, design, development, manufacturing, testing, shipping and support operation for consistent high quality. For medical devices, EN 46001 is awarded only to those companies which both satisfy the standards of ISO 9001 and comply with the European Union's Medical Device directive.
Sunrise is a refractive surgery company based in Fremont, California that is developing Holmium laser-based systems, which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand ("Sand Process") in correcting ophthalmic conditions. These systems(1) incorporate a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and over correction resulting from PRK and LASIK treatments for myopia. The system is currently used in Europe and the Americas, and is in clinical trials in the U.S.
Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgment, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements.
(1) Caution -- Investigational Device: Federal law restricts this device to investigational use in the U.S. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com.
CONTACT: Sunrise Technologies, Inc.
Investor Relations
Susan Lorigan, 510/623-9001
Ed Coughlan, 510/771-2399 |
